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ABSTRACT
Objective Paediatric clinical trials are often conducted
as multinational trials. Informed consent or assent is part
of the ethics committee approval for clinical trials. The
consent requirements vary between countries due to
national laws and regulations, which are not harmonised
in Europe. These discrepancies can present challenges
for paediatric clinical trials. The aim of this study was to
assemble these consent and assent requirements across
the European Economic Area. The collated national
requirements have not been publicly available before,
despite a real need for this data.
Methods National consent and assent requirements for
paediatric clinical trials were analysed and collated for
25 European Union Member States and 2 European Free
Trade Association countries until the end of 2014. The
data were retrieved from existing databases and through
communication with the competent authorities and
selected ethics committees. Results from a literature
search for international or national guidelines,
declarations and conventions and academic societies’
publications served as comparison material.
Results Consent and assent requirements are
heterogeneous across these countries. We compiled our
ﬁndings in ‘The Informed Consent and Assent Tool Kit’,
a table including 27 national consent and assent
requirements listed by individual country.
Conclusions Wide variation in paediatric consents and
assents presents challenges for multinational paediatric
trials in Europe. The toolkit is available for all those
involved in paediatric clinical trials and ethics
committees, providing a new platform for proactive
feedback on informed consent requirements, and may
ﬁnally lead to a needed harmonisation process, including
uniform standards accepted across Europe.
INTRODUCTION
Clinical trials (CTs) in children are often conducted
as multinational, multicentre trials, necessitated by
small patient populations, rarity of disease and
limited specialist facilities. As CTs need a separate
competent authority (CA) and ethics committee
(EC) approval in each participating country, the
pharmaceutical industry and investigators spend
much time and resources preparing documentation
and correspondence to these submissions.
In January 2007, the European Union (EU)
Paediatric Regulation ((European Commission) No
1901/2006)1 came into force requiring the conduct
of more paediatric CTs to facilitate the develop-
ment and accessibility of medicinal products for
children. A further EU CT Regulation will come
into force after 28 May 2016,2 but while this
harmonises the clinical trial application (CTA)
process, it does not address the diversity in review
and conduct of EC approvals at each site.
The process of obtaining EC approval (with
consent or assent requirements for children) is not
harmonised in the EU. Despite internationally
accepted ethical principles3–11 and several EU-level
guidelines,12–16 this area presents a major challenge
for paediatric CTs across the EU. Although the doc-
trine of consent is an ethical cornerstone of
medical research conducted in humans, special pro-
visions for children vary between and, in some
cases, within countries due to differences in
national laws and practices.
Within the European Economic Area (EEA),
three regulatory frameworks govern the conduct of
paediatric research: the Convention on Human
Rights and Biomedicine (the Oviedo
Convention);12 Directive 2001/20/EC (European
What is already known on this topic?
▸ There are noticeable differences between
national consent and assent requirements for
paediatric clinical trials in Europe due to
national laws and regulations.
▸ The international and the ethics societies’
guidelines are not based on uniform standards
and rarely provide detailed consent or assent
recommendations for children.
▸ A single source of comprehensive multinational
data on informed consent and assent
requirements of paediatric clinical trials across
Europe is not publicly available.
What this study adds?
▸ The ‘Informed Consent and Assent Tool Kit’ is a
publicly available resource for stakeholders
involved in the running of paediatric clinical
trials in Europe.
▸ These data provide a new platform for
proactive feedback from stakeholders to
maintain a common resource and approach to
consent and assent requirements in Europe.
▸ These data hope to promote discussion for
long-term decisions and practical changes
leading to uniform ethics committee procedures
across the European Economic Area.
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Commission Directive)14 and the Paediatric Regulation
((European Commission) No 1901/2006).1 Discrepancies exist
between these three frameworks. For example, the veto power
of a child to participate in research is not covered in the
Paediatric Regulation, while the Oviedo Convention allows a
more extensive decision-making capacity by the child than the
European Commission Directive, which relies on investigator’s
consideration of the explicit wish of a child. The aim of this
work is to describe the heterogeneity in consent and assent
requirements for paediatric CTs and to provide a tabulated
summary of these requirements by country as a tool for stake-
holders preparing paediatric CT submissions in the EEA.
METHODS
The working group (WG) of the European Network of
Paediatric Research at the European Medicines Agency
(Enpr-EMA) collected speciﬁc legal requirements of consent and
assent for children and adolescents from the national legislations
of 25 EU member states and 2 European Free Trade Association
(EFTA) countries (Norway and Iceland) during 2014. The
primary data source was a repository of EC submissions from
national authorities provided by the Contract Research
Organization (CRO), PRA Health Sciences (PRAHS).17
Secondary sources were publicly available data found on
national websites of regulatory authorities, such as Medicines
Agencies and National Ethics Committees. Additional data came
through Regulinx,18 a UK-based company specialised in consult-
ing on regulatory affairs, and from the Finnish Investigators
Network for Pediatric Medicines (FinPedMed).19
Table 1 provides a snapshot of the information collated in
2014. The data are arranged by country under three main head-
ings. The ﬁrst heading, ‘Consent/Assent from child’, includes
data on the legal age of consent and mandatory or suggested
age ranges deﬁned for assent (or consent if assent is not used).
The second heading, ‘Consent from parent(s)/guardian(s)’,
includes legal requirements for the number of required signator-
ies. The third heading, ‘General informed consent information’
includes ofﬁcial language requirements and consent template(s),
guidelines or additional national information with existing web
links.
In addition, the WG systematically searched online sources to
identify subject-related articles, learned societies’ recommenda-
tions and ethical guidelines, conventions and recommendations.
The search was conducted in the PubMed (US National Library
of Medicine, National Institutes of Health) database, EU
Commission website, national competent authorities’ websites
and Google sources using the keywords: ethics, guideline, regu-
lations, paediatric, minors, children, biomedical research, clin-
ical trials, human rights and children’s rights. The search
resulted in 28 relevant documents related to medical research
ethics on humans and, more speciﬁcally, on children. Ten had a
worldwide scope, nine a continental or national scope, and nine
were publications from academic societies.2–14 20–34 These docu-
ments were compared with the current ofﬁcial and legal recom-
mendations by verifying the consent-related and assent-related
texts of these documents.
Finally, personal experiences of the WG members (ie, in the
conducted multicentre trials and communication with ECs)
were used for supplementary comparison. Once all the data
sources for consent and assent requirements in the EEA had
been collated, the WG compared and analysed the sources of
discrepancy in practice across the jurisdictions. This revealed
several discrepancies, which are addressed in the discussion
section.
RESULTS
Assent and consent: differences in use and deﬁnitions
Both the term ‘consent’ and ‘assent’ are interpreted differently
in legal texts between EEA countries. Generally, each country’s
national legislation includes legal age ranges and requirements
for either consent or assent from a child, in addition to any
legal (parental or guardian) signatures. The deﬁnition of these
two terms rests on the need of these signatures: either given by
the trial subject alone, or in conjunction with the parents/guar-
dians. Usually, consent is deﬁned according to the legal age limit
of majority, which differs between countries. This is not the
case in all countries, like the Netherlands where infant informed
consent is needed, in addition to parental consent in children
between 12 and 17 years of age. Assent is a non-legal agree-
ment, and an additional parental/guardian signature (consent) is
always required before the participation of the child in a trial is
legally accepted.
Differences in consent and assent age limits and legal
signatures
In most of the EEA countries, 18 years is the legal age for inde-
pendent consent, but the following exceptions should be noted:
14 years in Austria, 15 years in Finland and Denmark and
16 years in the UK. These exceptions come with certain limita-
tions and with the obligation to notify parents/legal guardians.
However, across all the EEA countries, 32 different age group-
ings to the legal age exist for recommended additional assent or
consent needed from the child participating in the CT. These
groupings include, for example, 4–11 years, 12–14 years and
14–17 years. Only three countries (Croatia, Lithuania and
Slovakia) have not speciﬁed age groups for assent or consent.
Differences are also seen in the requirement of signatures
from parents or legal guardians. Seventeen countries (63%)
require signatures of both parents in addition to the child’s own
assent or consent. Speciﬁc guidelines with consent form tem-
plates and additional aid material (eg, pictures) for children in
paediatric CTs have been generally accepted by some EU
member states (eg, Finland and UK).
DISCUSSION
The United Nations Convention on the Rights of the Child
deﬁnes a child as everyone under 18, unless, ‘under the law
applicable to the child, majority is attained earlier’.3 For chil-
dren below that age, there are noticeable differences between
national and organisational regulations on ethical consent in
paediatric CTs. These concern speciﬁcally non-uniform age
limits and age ranges, different deﬁnitions for legal consent and
the requirement of parental or legal guardian signatures.
It appears that these criteria, for unknown reasons, are not
uniformly deﬁned in European guidelines or recommendations.
We also found that the international and the ethics societies’
guidelines and recommendations rarely detail consent or assent
procedures for children,7 13 27–31 but often very generic instruc-
tions without speciﬁc deﬁnitions.2–6 8–12 20–26 32–34 For the
greater part, these criteria do not seem to be based on the devel-
opmental stage of the child and his/her competency level for
informed consent or assent. Competency, in addition to health
condition, is important for determining further actions if trial
subjects reach the age of majority during the study and need to
give their own (legal) consent to continue.2
The terms ‘consent’ and ‘assent’ are also not deﬁned in
general guidelines and are not harmonised across the EEA.
Some European countries use the term consent for both minors
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Table 1 The Informed Consent and Assent Tool Kit—informed consent requirements for paediatric clinical trials in Europe
Consent/assent from child* Consent from parent(s)/guardian(s) General informed consent information
Country
Legal age
of consent†
Mandatory/suggested age
ranges defined for assent
(or consent if assent not
used)‡ Number of required signatories
Official language
requirements Consent template(s)/guidelines/information sources
Austria Not
specified
Practice––
14 years
8–13 years
EC may require younger
assents
Both parents German http://www.medunigraz.at/ethikkommission/Forum/index.htm
http://www.ethikkommissionen.at/
http://www.uibk.ac.at/strafrecht/scheil/
scheil-einfuehrung-in-die-arzneimittelpruefung-bei-kindern-und-jugendlichen---kks--kids-ip.pdf
Belgium 18 years 4–11 years (some sites do not
use under 12 years)
12–14 years
14–17 years
One parent at recruitment, but both
parents at some point for signatures
Dutch, French;
German at site request
http://www.fagg-afmps.be/en/human_use/medicines/medicines/research_development/ethic_
committee/templates_informed_consent/
Do not have paediatric templates
Bulgaria 18 years 6–11 years
12–14 years
14–17 years—use own
consent+parental signature
also required
Both parents Bulgarian No national EC websites available in English
Bulgarian Drug Agency -> clinical trials
http://en.bda.bg/index.php?option=com_
content&view=category&layout=blog&id=14&Itemid=34
Croatia Nothing
specified
Nothing specified Nothing specified Croatian Agency for Medicinal Products and Medical Devices of Croatia -> Central Ethics Committee ->
http://www.almp.hr/?ln=en&w=o_SEPu
Information on clinical trials not available in English.
Czech
Republic
18 years 7–11 years
12 years—own consent
12–14 years
15–17 years
Both parents. Only by one parent if
the other parent is not listed in the
child’s birth certificate, has died or is
younger than 18 years.
Czech. Where the child’s parents
(or one of them) are foreign
nationals, the information sheet
shall be presented in bilingual
format.
State Institute for Drug Control -> Details of clinical trials / Guidelines and Forms / KLH-22 V.1:
http://www.sukl.eu/medicines/klh-22-version-1
Denmark 18 years 15–17 years––proxy consent Both parents
Exception—no parents if aged 15–17
and non-interventional no-risk study
(EC dispensation required)
Danish The National Committee on Health Research Ethics -> Guidelines about notification
http://www.cvk.sum.dk/CVK/Home/English.aspx
http://cvk.sum.dk/English/guidelinesaboutnotification.aspx -> 4.4. Medicinal product trials and
clinical investigations of medicinal devices involving legally incompetent subjects; 4.4.1 Trials
with children and young people under the age of 18
http://cvk.sum.dk/English/guidelinesaboutnotification.aspx#Afsnit%205.0
Act on Research Ethics Review of Health Research Projects
Estonia 18 years 0–7 years
7–17 years––mandatory
Both parents Estonian State Agency of Medicine -> Clinical trials -> Conditions and procedure for conducting clinical
trials of medicinal products
http://www.ravimiamet.ee/en/clinical-trials-medicinal-products-estonia
Finland 15 years Written separate consent as
soon as child is literate; under
15 years––own consent
+parental consent;
15–17 years––own consent
+parental notification if minor
can understand the
significance of research+direct
health benefit is expected
Parent or legal guardian and the
child, when they are literate, need to
sign the consent. One parent by the
law, but the other one can be
informed (both can sign if they want).
Finnish, Swedish Medicines Research Act 488/1999
Medical Research Decree 986/1999
Additional info:
FinPedMed guidelines; legal and ethical regulation—templates for age groups 6–17 and
parents
Regulatory requirements for clinical trials in Finland
Picture cards to support IC process
Continued
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Table 1 Continued
Consent/assent from child* Consent from parent(s)/guardian(s) General informed consent information
Country
Legal age
of consent†
Mandatory/suggested age
ranges defined for assent
(or consent if assent not
used)‡ Number of required signatories
Official language
requirements Consent template(s)/guidelines/information sources
France 18 years Based on EC—usually two or
three age groups
4–6 years
7–12 years
13–17 years
Picture ICFs for young children
Both parents French Comité de Protection des Personnes Sud-Méditerranée II : http://www.cpp-sudmed2.fr/
Information-et-autorisation-des?lang=fr
National Consultative Ethics Committee for Health and Life Sciences:
http://www.ccne-ethique.fr/en
Germany 18 years 7–11 years
12–16 years
17 years––own consent
+parental consent required
Both parents German German Ethics Council;
http://www.ethikrat.org/—no information for clinical trials
Landesärztekammer Brandenburg—information available ONLY in German.
https://www.laekb.de/
ICF Guidance
https://www.laekb.de/files/146A97FF999/AMG_Patienteninfo_Kinder_7bis11.pdf
Hungary 18 years Under 6 years
6–10 years
11–14 years
15–17 years
One parent Hungarian National Institute of Pharmacy and Nutrition -> Laws and regulations (only available in
Hungarian) -> Miniszteri rendeletek
http://ogyei.gov.hu/search/index.php?searchPhrase=decree&from=10
http://www.ogyei.gov.hu/magyar_jogszabalyok/
-> Decree 35/2005 (VIII. 26.) of the Minister of Health on the clinical trial and application of
correct clinical practices of investigational medicinal products intended for use in humans
7§ Clinical trials conducted on minors
http://net.jogtar.hu/jr/gen/getdoc.cgi?docid=A0500035.eum
Iceland 18 years Under 12 years One parent—the EC can request both
parents’ signatures in some cases.
Icelandic or English. The study
objective in Icelandic. Materials
in Icelandic.
(For studies involving groups of
other ethnicity, an appropriate
language is required.)
The National Bioethics Committee
(http://www.vsn.is/en/node/189)
The Parliament; http://www.althingi.is/english -> http://www.althingi.is/lagasafn/
log-samthykkt-a-althingi/ ->
The Act of Law, No. 44/2014, on scientific research within the health sector defines the
conditions for biomedical research and the role of the bioethics committees
http://www.althingi.is/lagas/nuna/2014044.html
Several laws and regulations on data protection, medicines, biobanks and health information
collections (2014), etc
Ireland 16 years
(clinical
trials)
18 years
(all other
research)
7 years, or according to
capacity of child
One parent English List of Research Ethics Committees for clinical trials of IMP:
http://health.gov.ie/
european-communities-clinical-trials-on-medicinal-products-for-human-use-regulations-2004/
Research Ethics Committee Standard Application Form:
http://www.molecularmedicineireland.ie/research_ethics
National Consent Policy: http://www.hse.ie/eng/about/Who/qualityandpatientsafety/National_
Consent_Policy/consenttrainerresource/trainerfiles/NationalConsentPolicyDOC.html
Clinical Trial Regulation: S.I. No. 190/2004—European Communities (Clinical Trials on Medicinal
Products For Human Use) Regulations, 2004
http://www.irishstatutebook.ie/2004/en/si/0190.html
Continued
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Table 1 Continued
Consent/assent from child* Consent from parent(s)/guardian(s) General informed consent information
Country
Legal age
of consent†
Mandatory/suggested age
ranges defined for assent
(or consent if assent not
used)‡ Number of required signatories
Official language
requirements Consent template(s)/guidelines/information sources
Italy 18 years 6–10 years
11–14 years
15–17 years––with own
signature
No official mandatory age(s)
for assent. Different
age-tailored assents are
submitted voluntarily, and are
evaluated by the ECs
Both parents Italian The Italian Medicines Agency http://www.agenziafarmaco.gov.it/en/content/clinical-trials
the Italian regulation on CTs include the following:
D.lgs 211/2003 http://www.agenziafarmaco.gov.it/sites/default/files/decreto_24062003_inglese.
pdf
DM 21/12/07 https://www.agenziafarmaco.gov.it/ricclin/sites/default/files/files_wysiwyg/files/
Normativa/MD_21_December_2007_CTAform_English.pdf
Latvia 18 years 0–7 years
7–17 years
One parent or legal representative Latvian State Agency of Medicines of the Republic of Latvia -> Clinical trials and non-interventional
trials -> legislation
http://www.zva.gov.lv/?setlang=en -> http://www.zva.gov.lv/?id=396&sa=396&top=386 ->
http://www.zva.gov.lv/index.php?id=381&sa=381&top=333&lang
http://www.zva.gov.lv/doc_upl/MK_not_289_English_02062010.pdf
Lithuania 18 years No set ages Both parents Lithuanian The Lithuanian Bioethics Committee -> Biomedical Research -> favourable opinion on clinical
drug trial
http://bioetika.sam.lt/index.php?3202747546
Informed Consent
http://bioetika.sam.lt/index.php?3221858831 ->
http://bioetika.sam.lt/index.php?577320631—information available only in Lithuanian
http://bioetika.sam.lt/index.php?3202747546
Malta 18 years 6–17 years Parents or legal representative
Practice—both parents
One of the official languages of
Malta (eg, Maltese) or in a
language
understandable to the clinical
trial subject and/or his legal
representative.
Malta Health Ethics Committee
https://health.gov.mt/en/appbodies/hec/Pages/Links.aspx
Maltese Clinical Trials Regulations 2004 (LN490 of 2004) MEDICINES ACT, 2003 (ACT NO. III OF
2003); http://justiceservices.gov.mt/DownloadDocument.aspx?app=lp&itemid=16860&l=1
The
Netherlands
18 years 12–17 years Both parents.
If parents are divorced and they both
have parental rights, they both have
to sign. For a single parent, without
another partner with parental rights,
one signature is enough.
Dutch Central Committee on Research Involving Human Subjects (CCMO) -> Human Subject ->
Informed Consent—information available only in Dutch.
http://www.ccmo.nl/en/ -> http://www.ccmo.nl/en/minors
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Table 1 Continued
Consent/assent from child* Consent from parent(s)/guardian(s) General informed consent information
Country
Legal age
of consent†
Mandatory/suggested age
ranges defined for assent
(or consent if assent not
used)‡ Number of required signatories
Official language
requirements Consent template(s)/guidelines/information sources
Norway 18 years 16–17 years––with own
signature
12–16 years––in special
circumstances
Main rule: both parents sign the
consent form if they have parental
responsibility for the child.
Required for all children under
12 years old.
Norwegian The Norwegian National Research Ethics Committees -> Clinical Trials -> Regulations
https://www.etikkom.no/en/ethical-guidelines-for-research/
http://www.legemiddelverket.no/English/Clinical_trials/Regulations/Documents/Norwegian%
20regualtion%20for%20Clinical%20Trials.pdf
National database for Laws and Acts -> Lov om medisinsk og helsefaglig forskning
(helseforskningsloven)—information available only in Norwegian.
https://lovdata.no/dokument/NL/lov/2008-06-20-44?q=helseforskning
Act on medical and health research (Helseforsknings-loven)
Guidance to Helseforsknings-loven (in Norwegian only) Additional info:
Norwegian Medicines Agency: Website on clinical trials.
Poland 18 years 6–11 years
12–15 years
16–17 years
One parent
Practice—both parents
Polish http://www.eurecnet.org/information/poland.html
No national EC websites available in English
Portugal 18 years 0–8 years
8–12 years
12–17 years
Both parents Portuguese http://www.eurecnet.org/information/portugal.html
CEIC—National Ethics Committee for Clinical Research
http://www.infarmed.pt/portal/page/portal/CEIC/English
No national regulations/acts available in English
Romania 18 years Under 6 years
6–10 years
11–14 years
15–18 years
Both parents Romanian National Ethics Committee of Romania
http://www.adsm.ro/ro/comisia+nationala+de+bioetica+a+medicamentului+si+a+dispozitivelor
+medicale#
No information available in English
Scotland
(UK)
16 years 0–5 years
6–10 years
11–15 years
Consent with own signature
under 16 years, if they are
competent to do so
One parent English NRES Guidance
http://www.hra-decisiontools.org.uk/consent/principles-children.html and
http://www.ukctg.nihr.ac.uk/default.aspx
Slovakia n.a. n.a. n.a. Slovakian The State Institute for Drug Control (SIDC) -> Clinical trials -> Instructions
http://www.sukl.sk/en?page_id=256 ->
http://www.sukl.sk/en/clinical-trials/instructions?page_id=2821
No national regulations/acts available in English
Slovenia 18 years 9 years—assent
15 years—with own signature
One parent Slovenian Republic of Slovenia National Medical Ethics Committee ->
http://kme-nmec.si/—only front page
No additional information available.
Spain 18 years 0–11 years
12–17 years––with own
signature
One parent Spanish The Agencia Española de Medicamentos y Productos Sanitarios (AEMPS); A state agency within
the Spanish Ministry of Health, Social Services and Equality -> Medicines for Human use—>
Clinical research with medicines
http://www.aemps.gob.es/en/investigacionClinica/medicamentos/home.htm
The Ministry of Health, section about regulation of clinical trials:
http://www.aemps.gob.es/en/legislacion/espana/investigacionClinica/ensayos.htm
The Spanish Regulation about Clinical trials: the ROYAL DECREE 223/2004-section 7.3 (English
version is available by request)
Continued
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Table 1 Continued
Consent/assent from child* Consent from parent(s)/guardian(s) General informed consent information
Country
Legal age
of consent†
Mandatory/suggested age
ranges defined for assent
(or consent if assent not
used)‡ Number of required signatories
Official language
requirements Consent template(s)/guidelines/information sources
Sweden 18 years Written separate consent as
soon as child is literate
6–10 years
11–14 years
15–17 years––with own
signature
Both parents and the child, when
literate, need to sign the consent
Swedish The Central Ethical Review Board -> Documents -> Information for Research Participants
http://www.epn.se/en/start/the-organisation/ -> http://www.epn.se/en/start/
central-ethical-review-board-documents/ -Etikprövningslagen 2008.
Regulatory requirement for clinical trials LVFS 2011:19
Läkemedelslagen—1992
Biobank law––2002
Personal Data Act 1998
National Medicines Agency -> Legislation -> Codes of Statutes -> 1996:17 Clinical trials of
medicinal products
https://lakemedelsverket.se/english/ -> https://lakemedelsverket.se/english/overview/Legislation/
Codes-of-statutes/
UK 16 years 0–5 years
6–10 years
11–15 years
One parent English NRES Guidance;
http://www.hra-decisiontools.org.uk/consent/principles-children.html and
http://www.ukctg.nihr.ac.uk/default.aspx
© European Medicines Agency, 2015. Reproduced with permission
*Consent/assent from child: this information has been mainly collected via the normal daily work and notes of the CRO Company, PRA Health Sciences (UK), when preparing EC submissions for national authorities. Some of this information is not available
in English, nor publicly available in regulatory authority’s web pages. In addition, some English-translated text versions may include inaccurate terms or explanations, which could give rise to different interpretations. Therefore, the authors cannot
guarantee 100% accuracy for all national requirements. In addition, this table is a snapshot of the data gathered in 2014, which might have subsequently changed.
†Legal age of consent: legal age of consent means the age from which a child is able to give and sign their own independent legally valid consent according to the national law/act/regulation. Children below this age limit are incapable of giving legal
informed consent and need parental/legally authorised guardian’s informed consent with a signature to participate in a clinical study. Parental/legally authorised guardian’s informed consent may be obtained/sought in addition to the child’s own consent/
assent, or when the child above the age limit is incapable to sign consent due to a difficult physical condition.
‡Mandatory/suggested age ranges defined for assent (or consent if assent not used): these mandatory or suggested age ranges are defined in national regulation/law/act, for a child below the legal age of consent and for own informed consent or assent
(depending on the terminology used in legal texts). This consent or assent is obtained in addition to the legally valid parental/legally authorised guardian’s signed informed consent. This type of child’s own assent/consent supports the child’s integrity and
rights, creates the opportunity to hear their own opinion, supposed will and possible dissent, thus respecting the child’s autonomy in the informed consent process.
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(older children below legal adult age) and parents (legal guar-
dians). Usually, the term assent refers to a child’s or minor’s
agreement to the trial (not legally valid on its own), while
consent is documented through legal signature(s) by the parents
(guardians) or the child, when the child is above the legal age.
There are more than 1000 ECs in Europe,35 which result in
substantial variability of EC compositions and practices,36–38
with consequently a certain degree of inconsistency in the
required consent and assent documentation for multinational
and multicentre trials. Moreover, much time and resources may
be needed to obtain approvals. To manage these inconsistencies
and to reduce the duplicative workload, sponsors are recom-
mended to perform an iterative or sequential review at each par-
ticipating institution or country.
The European Medicines Agency (EMA) has evaluated the
impact of the Paediatric Regulation after its ﬁrst 5 years of being
in force.39 So far, the regulation has not yet led to more paediat-
ric CTs in Europe, although there are plans to conduct CTs with
enrolment of more children.39 Still, the initiation of new CTs
may be hampered by the practical obstacles of complex EC
processes.
Currently, it is not possible to seek European-wide legislative
changes for EC practice harmonisation, as the practice for one
EC will not necessarily work for another without concerted
effort to achieve harmony. However, an expert group has
designed model consent and assent forms for different paediat-
ric age groups,40 which could be applied across Europe.
Furthermore, better deﬁnitions of the concepts of ‘understand-
ing’, ‘capability’, ‘capacity for autonomous decisions’ and
‘moral understanding of altruism’ could greatly support a har-
monisation process.
To solve these problems, we suggest the following measures:
▸ Uniform, commonly accepted standards and guidance across
Europe/EEA
▸ Deﬁnition of the lowest age limit to consent and assent
requiring own signatures in addition to parental (legal)
consent until the legal age of majority permits independent
consent
▸ Fundamental discussion to create more detailed deﬁnitions
of assent and consent and to decide whether these terms
could be harmonised and used with similar principles for
paediatric population
▸ Standardised structure and reading level requirements of
consent and assent documents, including recommendations
for legal guardian’s (parental) signatures
▸ A master consent/assent template in all national languages
being publicly and readily available.
‘The Informed Consent and Assent Tool Kit’ was updated
mainly until the end of 2014. As national-level regulations and
laws may change over different intervals, the accuracy of the
data and linked documents are dependent upon regular review.
The Enpr-EMA’s central aim is to enhance and promote the
conduct of paediatric CTs in Europe. This toolkit being publicly
available free of cost on the Enpr-EMA website meets this aim.
Please go to: http://www.ema.europa.eu/Partners&Networks/
Networks/Enpr-EMA/Enpr-EMA activities, or directly at: http://
tinyurl.com/h2xrlvr. With this toolkit, we hope that all stake-
holders will proactively provide feedback via the Enpr-EMA, to
keep this toolkit up to date and fostering discussion on harmon-
isation of EC procedures needed for paediatric trials across
Europe.
Acknowledgements Special thanks go out to other partners of our original
working group, Ivana Silva (EMA), Dr Richard Trompeter (GOSH/IPTA, UK) and
Dr Alan Boddy (previously Newcastle University/currently, the University of Sydney)
for their help in preparing the initial report for Enpr-EMA.
Contributors Literature search was done by PL, AN, JM, PS and DN; data
collection and ﬁgures were done by PL, JM, PS and AN; Data interpretation, writing
and approval of ﬁnal version were done by all authors.
Funding This research has received funding from the European Union’s Seventh
Framework Programme for research, technological development and demonstration
under grant agreement no. 261060 (Global Research in Paediatrics—GRiP network
of excellence).
Competing interests None declared.
Provenance and peer review Commissioned; externally peer reviewed.
Open Access This is an Open Access article distributed in accordance with the
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which
permits others to distribute, remix, adapt, build upon this work non-commercially,
and license their derivative works on different terms, provided the original work is
properly cited and the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/4.0/
REFERENCES
1 European Union. Regulation (EC) No 1901/2006 of the European Parliament and of
the Council of 12 December 2006 on medicinal products for paediatric use and
amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/
EC and Regulation (EC) No 726/2004. 26 January 2007. http://ec.europa.eu/health/
ﬁles/eudralex/vol-1/reg_2006_1901/reg_2006_1901_en.pdf (accessed 16 Dec
2014).
2 European Union. Regulation EU No 536/2014 of the European Parliament and of
the Council of 16 April 2014 on clinical trials on medicinal products for human use,
and repealing Directive 2001/20/EC. 16 June 2014 (will become applicable no
earlier than 28 May 2016). http://ec.europa.eu/health/human-use/clinical-trials/
regulation/index_en.htm (accessed 16 Dec 2014).
3 United Nations Human Rights. Convention on the Rights of the Child. Adopted and
opened for signature, ratiﬁcation and accession by General Assembly resolution 44/
25 of 20 November 1989, entry into force 2 September 1990, in accordance with
article 49. 1990. http://www.ohchr.org/en/professionalinterest/pages/crc.aspx
(accessed 15 Dec 2014).
4 United Nations. The Universal Declaration of Human Rights. 1948. http://www.un.
org/en/documents/udhr/ (accessed 15 Dec 2014).
5 World Medical Association. WMA Declaration of Helsinki—Ethical Principles for
Medical Research Involving Human Subjects. 64th WMA General Assembly,
Fortaleza, Brazil, October 2013. http://www.wma.net/en/30publications/10policies/
b3/ (accessed 15 Dec 2014).
6 International Conference of Harmonization. ICH Guideline for good Clinical Practice
E6 (R1). 1996. http://www.ich.org/products/guidelines/efﬁcacy/article/
efﬁcacy-guidelines.html (accessed 16 Dec 2014).
7 International Conference of Harmonization. ICH E 11- Clinical Investigation of
Medicinal Products in the Paediatric Population. 2000. http://www.ich.org/products/
guidelines/efﬁcacy/article/efﬁcacy-guidelines.html (accessed 16 Dec 2014).
8 The Council for International Organizations of Medical Sciences (CIOMS) in
collaboration with the World Health Organization (WHO)—International Ethical
Guideline for Biomedical Research Involving Human Subjects. 2002. http://www.
cioms.ch/publications/layout_guide2002.pdf (accessed 15 Dec 2014).
9 World Health Organization. WHO Guidelines for good clinical practice (GCP) for
trials on pharmaceutical products. Technical Report Series, No. 850, 1995, Annex
3. 1995. http://www.nus.edu.sg/irb/Articles/WHO%20GCP%201995.pdf (accessed
15 Dec 2014).
10 World Health Organization. WHO Handbook for Good Clinical Research Practice
(GCP) Guidance for Implementation. 2002. http://apps.who.int/prequal/info_general/
documents/GCP/gcp1.pdf (accessed 15 Dec 2014).
11 United Nations Educational, Scientiﬁc and Cultural Organization. UNESCO Universal
Declaration on Bioethics and Human Rights. Adopted by acclamation by the 33rd
session of the General Conference of UNESCO on 19 October 2005. http://www.
unesco.org/new/en/social-and-human-sciences/themes/bioethics/
bioethics-and-human-rights/ (accessed 15 Dec 2014).
12 Council of Europe—ETS no.164—Convention for the Protection of Human Rights
and Dignity of the Human Being with regard to the Application of Biology and
Medicine: Convention on Human Rights and Biomedicine. Oviedo, 4.IV.1997. http://
conventions.coe.int/Treaty/en/Treaties/Html/164.htm (accessed 15 Dec 2014).
13 European Union Commission ad hoc group. Recommendations of the Ad hoc group
for the development of implementing guidelines for Directive 2001/20/EC relating to
good clinical practice in the conduct of clinical trials on medicinal products for
human use. Ethical Considerations for Clinical Trials on Medicinal Products
Conducted with the Paediatric Population. 06 October 2008. http://ec.europa.eu/
health/ﬁles/paediatrics/docs/paeds_ethics_consultation20060929_en.pdf (accessed
9 Feb 2015).
1024 Lepola P, et al. Arch Dis Child 2016;101:1017–1025. doi:10.1136/archdischild-2015-310001
Original article
group.bmj.com on December 9, 2016 - Published by http://adc.bmj.com/Downloaded from 
14 EU Commission. Directive 2001/20/EC of the European Parliament and of the
Council of 4 April 2001 on the approximation of the laws, regulations and
administrative provisions of the Member Status relating to the implementation of
good clinical practice in the conduct of clinical trials on medicinal products for
human use. Ofﬁcial Journal of the European Communities 2011. L 121/34–44.
http://ec.europa.eu/health/human-use/clinical-trials/directive/index_en.htm (accessed
16 Dec 2014).
15 European Commission. EudraLex—Volume 10 Clinical trials guidelines, Chapter I:
Application and Application Form; Detailed guidance on the application format and
documentation for Ethics Committees opinion. February 2006. http://ec.europa.eu/
health/documents/eudralex/vol-10/index_en.htm (accessed 16 Dec 2014).
16 European Commission. Enterprise and Industry Directorate-General, Consumer
goods, Pharmaceuticals. Detailed guidance on the application format and
documentation to be submitted in an application for an Ethics Committee
opinion on the clinical trial on medicinal products for human use, February
2006. http://ec.europa.eu/health/ﬁles/eudralex/vol-10/12_ec_guideline_
20060216_en.pdf
17 PRA Health Sciences International, http://prahs.com/ (accessed 9 Feb 2015).
18 Regulinx, UK, http://www.regulinx.eu/ (accessed 9 Feb 2015).
19 FinPedMed, Finland, http://www.ﬁnpedmed.ﬁ/index.php?page=107&lang=2
(accessed 9 Feb 2015).
20 Health Canada—Requirements for Informed Consent. 2014. http://www.hc-sc.gc.ca/
sr-sr/advice-avis/reb-cer/consent/index-eng.php (accessed 16 Dec 2014).
21 U.S. Department of Health and Human Services, U.S. Food and Drug Administration
—CFR Code of Federal Regulations, Title 21; Parts 50, 201 and 814. 50. http://
www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=50, 201
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?
CFRPart=201, 814 http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/
CFRSearch.cfm?CFRPart=814 (accessed 16 Dec 2014).
22 Medical Research Council (MRC) Ethics Guide. Medical research involving children.
UK Medical Research Council 2004. http://www.mrc.ac.uk/documents/pdf/
medical-research-involving-children/ (accessed 9 Feb 2015).
23 Canada, T.G.o. TCPS 2—2nd edition of Tri-Council Policy Statement:Ethical Conduct
for Research Involving Humans, 2010. http://www.pre.ethics.gc.ca/eng/
policy-politique/initiatives/tcps2-eptc2/default/
24 U.S. Department of Health and Human Services. Basic HHS Policy for Protection of
Human Research Subjects (“The Common Rule”) 45CFR46.
25 Field MJ, Behrman RE, Institute of Medicine (US) Committee on Clinical Research
Involving Children. Ethical Conduct of Clinical Research Involving Children.
Washington DC: National Academies Press (US), 2004.
26 Van’t Hoff W., Offringa M, for the Star Child Health group. StaR Child Health:
developing evidence-based guidance for the design, conduct and reporting of
paediatric trials. Arch Dis Child 2015;100:189–92.
27 Shaddy RE, Denne S. C, the Committee on Drugs and Committee on Pediatric
Research of the American Academy of Pediatrics. Guidelines for the Ethical Conduct
of Studies to Evaluate Drugs in Pediatric Populations. Guidelines for the Ethical
Conduct of Studies to Evaluate Drugs in Pediatric Population. Pediatrics
2010:,125:;850–60.
28 De Lourdes Levy M, Larcher V, Kurz R, Ethics Working Group of the Confederation
of European Specialists in Paediatrics (CESP). Informed consent/assent in children.
Statement of the Ethics Working Group of the Confederation of European Specialists
in Paediatrics (CESP). Eur J Pediatr 2003;162:629–33.
29 Modi N, Vohra J, Preston J, et al., Working Party of the Royal College of Paediatrics
and Child Health. Guidance on clinical research involving infants, children and
young people: an update for researchers and research ethics committees. Arch Dis
Child 2014;99:887–91.
30 Gill D, Ethics Working Group of the Confederation of European Specialists in
Paediatrics. Ethical principles and operational guidelines for good clinical practice in
paediatric research. Recommendations of the Ethics Working Group of the
Confederation of European Specialists in Paediatrics (CESP). Eur J Pediatr
2004;163:53–7.
31 McIntosh N. Child Health: Ethics Advisory Committee, Royal College of Paediatrics.
Guidelines for the ethical conduct of medical research involving children. Arch Dis
Child 2000;82:177–82.
32 Gill D, Crawley FP, LoGiudice M, et al. Ethics Working Group of the Confederation
of European Specialists in Pediatrics. Guidelines for informed consent in biomedical
research involving paediatric populations as research participants. Eur J Pediatr
2003;162:455–8.
33 Sauer PJ, Ethics Working Group, Confederation of European Specialists in Paediatrics
(CESP). Research in children. A report of the Ethics Working Group of the CESP.
Eur J Pediatr 2002;161:1–5.
34 ERIC Compendium. Ethical Research Involving Children; Ethical Guidance: Informed
Consent, 2013. http://childethics.com/wp-content/uploads/2013/10/
ERIC-compendium-Ethical-Guidance-Informed-consent-section-only.pdf (accessed 25
Feb 2015).
35 Altavilla A, Manfredi C, Baiardi P, et al. Impact of the new european paediatric
regulatory framework on ethics committees: overview and perspectives. Acta
Paediatr 2012;101:e27–32.
36 Hernandez R, Cooney M, Dualé C, et al. Harmonisation of ethics committees’
practice in 10 European countries. J Med Ethics 2009;35:696–700.
37 Veerus P, Lexchin J, Hemminki E. Legislative regulation and ethical governance of
medical research in different European Union countries. J Med Ethics
2014;40:409–13.
38 Legislation on biotechnology in the Nordic countries—an overview 2014.
NordForsk, 2014 Stensberggata 25 N–0170 Oslo, http://www.nordforsk.org. ISSN
1504-8640 http://www.nordforsk.org/en/publications/publications_container/
legislation-on-biotechnology-in-the-nordic-countries-2013-an-overview-2014/view
(accessed 11 Dec 2014).
39 5-year Report to the European Commission. General report on the experience
acquired as a result of the application of the Paediatric Regulation. 8 July 2012,
EMA/428172/2012, Human Medicines Development and Evaluation Human
Medicines Special Areas Sector. http://ec.europa.eu/health/ﬁles/paediatrics/2012-09_
pediatric_report-annex1-2_en.pdf (accessed 13 Dec 2013).
40 FINPEDMED: Document templates. Trial Information and informed consent
document templates. http://www.ﬁnpedmed.ﬁ/index.php?page=1255&lang=2
(accessed 25 Feb 2015).
Lepola P, et al. Arch Dis Child 2016;101:1017–1025. doi:10.1136/archdischild-2015-310001 1025
Original article
group.bmj.com on December 9, 2016 - Published by http://adc.bmj.com/Downloaded from 
in Europe
Informed consent for paediatric clinical trials
Neubauer and Saskia de Wildt
Pirkko Lepola, Allison Needham, Jo Mendum, Peter Sallabank, David
doi: 10.1136/archdischild-2015-310001
2016
2016 101: 1017-1025 originally published online May 25,Arch Dis Child 
 http://adc.bmj.com/content/101/11/1017
Updated information and services can be found at: 
These include:
References
 #BIBLhttp://adc.bmj.com/content/101/11/1017
This article cites 11 articles, 6 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by-nc/4.0/non-commercial. See: 
provided the original work is properly cited and the use is
non-commercially, and license their derivative works on different terms, 
permits others to distribute, remix, adapt, build upon this work
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
This is an Open Access article distributed in accordance with the Creative
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (120)Research and publication ethics
 (98)Legal and forensic medicine
 (60)Informed consent
 (192)Open access
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on December 9, 2016 - Published by http://adc.bmj.com/Downloaded from 
